BackgroundMigraine follow-up is difficult for outpatients, especially after the COVID-19 pandemic, we tried to identify the most appropriate telemedicine methods for migraine in terms of efficacy, safety, patient compliance, and patient and physician satisfaction.MethodsMigraine patients were screened from the Headache Center of the First Affiliated Hospital of Chongqing Medical University from September 2019 to December 2021 and randomly classified into an outpatient group and four telemedicine groups: social software, telephone, E-mail, and short message. Headache specialists followed up with the patients 3 and 6 months after their visit and asked about their satisfaction with the follow-up in each instance, as were the headache specialists.ResultsA total of 147 migraine patients were included, of whom 65 completed the follow-up. After 3 and 6 months of follow-up, the proportion of patients whose monthly headache frequency decreased by over 50% in the social-software, telephone, and E-mail groups was no different from that in the outpatient group. A similar result was obtained from evaluations with the Visual Analog Scale, the Headache Impact Test and the Migraine Disability Assessment compared with baseline in social software and telephone groups. The compliance in social-software group was not worse than that in the outpatient group. The proportion of patients in the E-mail group who completed the follow-up and the proportion of patients in the telephone group who consistently took preventive medication were significantly lower than those in the outpatient group. After 6 months, the majority of patients in the outpatient, social-software, and telephone groups and headache specialists in the outpatient, social-software groups were satisfied with the follow-up, while fewer patients in the E-mail group and fewer specialists in the telephone and E-mail group showed their satisfaction.ConclusionCompared with outpatient visits, it is safe and effective to use social software and telephone to follow up on migraine patients, and E-mail and short-message follow-up have lower feasibility. Migraine patients prefer social-software and telephone follow-up, while specialists prefer social-software follow-up.
Background: It is difficult to discriminate between headache attributed to transient ischaemic attack from migraine with aura. We studied the characteristics of headache-attributed transient ischaemic attacks to provide clinical evidence for the treatment of headache attributed to transient ischaemic attack.Methods: We performed a prospective study with a retrospective baseline evaluation of all patients with headaches attributed to transient ischaemic attack (22) during a three-year period. The demography, vascular risk factors and clinical information were collected. The following typical symptoms were evaluated by an ABCD2 score of 4 or greater. The headache characteristics were collected within a 24-hour interval after the onset of transient ischaemic attack.Results: Headache that is attributed to transient ischaemic attack accounted for 8.2% (22/269) of the patients with transient ischaemic attack. Headache attributed to transient ischemic attack was more common in women (68.2%, 15/22) and in posterior circulation of transient ischemic attack (59.1%,13/22). These types of headaches were similar to tension-type headache and included a bilateral location (72.7%, 16/22), a dull quality (72.7%, 16/22), and a moderate intensity (54.5%, 12/22).Conclusions:Our study showed that headache attributed to transient ischaemic attack was similar to a tension-type headache and was more common in women and in patients with posterior circulation transient ischaemic attacks.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.